Symbol | Exchange | Currency | |||
---|---|---|---|---|---|
AZN | · | NASDAQ | · | USD | |
AZNl | · | BATS Europe | · | GBP | |
AZNs | · | BATS Europe | · | SEK | |
AZNCF | · | OTC Markets | · | USD | |
3SAZ | · | London | · | GBP | |
AZN | · | London | · | GBP | |
3LAZ | · | London | · | GBP | |
AZNN | · | Mexico | · | MXN | |
AZNN | · | BIVA | · | MXN | |
AZN | · | Stockholm | · | SEK | |
AZNPy | · | TradeGate | · | EUR | |
AZNPy | · | Frankfurt | · | EUR | |
AZN | · | Xetra | · | EUR | |
AZN | · | TradeGate | · | EUR | |
AZN | · | Frankfurt | · | EUR | |
AZNm | · | Buenos Aires | · | ARS | |
A1ZN34 | · | B3 | · | BRL | |
AZNA | · | Vienna | · | EUR |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Financial Outlook | Delve into AstraZeneca's financial health, with analysts setting an average price target of $88, reflecting potential upside amid strong dividend performance |
Market Dynamics | Explore AstraZeneca's strategic positioning in competitive markets, balancing established presence with innovative approaches in hematologic malignancies |
Oral PCSK9 Potential | AZD0780, an oral PCSK9 inhibitor, emerges as a potential blockbuster with projected peak sales exceeding $5 billion, pending regulatory approval |
Pipeline Powerhouse | AstraZeneca's robust drug pipeline, spanning oncology to respiratory diseases, positions it for significant growth in the biopharmaceutical industry |
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNPeersSector | |
---|---|---|---|---|
P/E Ratio | 27.6x | 17.9x | −0.5x | |
PEG Ratio | 1.22 | 0.05 | 0.00 | |
Price / Book | 5.2x | 3.7x | 2.6x | |
Price / LTM Sales | 3.9x | 2.4x | 3.2x | |
Upside (Analyst Target) | 19.1% | 8.1% | 44.6% | |
Fair Value Upside | Unlock | 27.1% | 6.5% | Unlock |